about
A comparison of the aldosterone-blocking agents eplerenone and spironolactoneGlobal array-based transcriptomics from minimal input RNA utilising an optimal RNA isolation process combined with SPIA cDNA probesThe accuracy of symptoms, signs and diagnostic tests in the diagnosis of left ventricular dysfunction in primary care: a diagnostic accuracy systematic review.Differential expression and synthesis of natriuretic peptides determines natriuretic peptide receptor expression in primary cultures of human proximal tubular cells.Does the aldosterone:renin ratio predict the efficacy of spironolactone over bendroflumethiazide in hypertension? A clinical trial protocol for RENALDO (RENin-ALDOsterone) study.The association between serum urate levels and arterial stiffness/endothelial function in stroke survivors.Effect of vitamin D on blood pressure: a systematic review and meta-analysis.Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trialCareful screening to target interventions to prevent sudden cardiac death.The role of C-type natriuretic peptide in cardiovascular medicine.High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid.Impact of allopurinol use on urate concentration and cardiovascular outcomeAldosterone: cardiovascular assault.Pulse wave analysis and pulse wave velocity: a critical review of their strengths and weaknesses.Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease.Exercise training as a therapy for chronic heart failure: can older people benefit?Agreement between community echocardiography and hospital echocardiography in patients suspected of having left ventricular systolic dysfunctionQT interval abnormalities are often present at diagnosis in diabetes and are better predictors of cardiac death than ankle brachial pressure index and autonomic function testsB-type natriuretic peptide can detect silent myocardial ischaemia in asymptomatic type 2 diabetesB-type natriuretic peptide identifies silent myocardial ischaemia in stroke survivorsFurosemide responsiveness, non-adherence and resistance during the chronic treatment of heart failure: a longitudinal studySpironolactone reduces brachial pulse wave velocity and PIIINP levels in hypertensive diabetic patients.The clinical implications of aldosterone escape in congestive heart failure.B-type natriuretic peptide is an independent predictor of endothelial function in man.The prognostic value of high sensitivity troponin T 7 weeks after an acute coronary syndrome.The clinical pharmacology of angiotensin converting enzyme inhibitors in chronic heart failure.Sarcopenia--a potential target for Angiotensin-converting enzyme inhibition?Genetic variants predicting left ventricular hypertrophy in a diabetic population: a Go-DARTS study including meta-analysis.Interactions between atrial natriuretic factor and the autonomic nervous system.Assessment of arterial stiffness, a translational medicine biomarker system for evaluation of vascular risk.A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction.Therapeutic development in cardiac syndrome X: a need to target the underlying pathophysiology.More than skin deep: atherosclerosis as a systemic manifestation of psoriasis.Oxidative stress in renal dysfunction: mechanisms, clinical sequelae and therapeutic options.Meta-analysis of B-type natriuretic peptide's ability to identify stress induced myocardial ischemia.Mineralocorticoid antagonism: a novel way to treat sarcopenia and physical impairment in older people?The effect of metformin on insulin resistance and exercise parameters in patients with heart failure.Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice.Insulin sensitization therapy and the heart: focus on metformin and thiazolidinediones.Aortic valvular heart disease: Is there a place for angiotensin-converting-enzyme inhibitors?
P50
Q28276162-F21AB1DC-ABFB-4F3C-9F33-7CEBBFB95293Q28741725-0A69AF4B-80D7-429E-A137-1BD1481D02F3Q30484159-F9432F28-A440-48F8-A8CF-44C5888F574DQ32048291-8814049D-121C-4E75-BB54-FFE768D3307EQ33284161-3ED7FB6C-85EB-47EC-A70B-C0D6A176A740Q33317865-7B32D433-DC28-4723-8C39-DAAB369FAEABQ33479951-11527BE9-E058-4CF3-91DA-CBA992420A2CQ33935192-FB04DB97-B3DB-4193-926D-964689350908Q34173191-31EA7E26-27E2-44A9-9F82-47DFBA0E7FF6Q34294718-DAA29197-C09C-4E97-9ADD-1DC3ECE21CB8Q34585155-7D386175-81A3-4690-9169-A0D10D3096BBQ34830158-66BD0E35-00EB-43DB-A1E6-EF5A88C6359AQ34992148-04A13408-FC19-4695-9B96-90950BCC42B1Q35086230-27950F86-8DF3-40EB-B9CC-6131A328C0F6Q35108913-7FA3369C-5DE1-49C3-844A-8E0AD1E7C736Q35129801-D3FD4D39-8660-490D-86CB-D4E1222B5DB0Q35523272-0DB01D2D-5C58-4A75-819F-BE3FF6AE98AEQ35583422-F7D1582A-BB62-4621-A8F7-8E2FA4171EF5Q35771005-8A5CA9B0-D427-427A-B638-284CBC9E2AF6Q35771545-9D40F114-8257-4890-BB8F-709284348D9FQ35826083-C727FD8C-D54B-4D6B-8EA0-03A56921151EQ35826976-F93B1341-0D59-4352-B5B2-1A3C65C772ABQ35859269-DC8E40B4-B35A-4490-BE7B-EC7B0A7EB78AQ35964757-700F08CB-E071-4213-B3B7-5502DA923EA2Q36084618-E7502C32-F68B-4BDF-8B97-547A20420058Q36368960-912FF728-C4F7-4E0D-9A85-8DA01EAB5D64Q36540283-2D614DC0-9AC9-45D3-8ED6-080AF9886DA7Q37059805-0BDEE81D-C706-404C-A6E9-8FFE633FF5E3Q37135306-964C6D07-D74C-4EED-817F-76BECE9A2152Q37266665-972B54AA-0CE8-470B-8FFD-0DC2D5897D26Q37368707-3BAA4FF3-9060-41AC-8E41-03395F82230DQ37389672-86588AD1-27AB-4CF4-B993-1FF8BAA8CD49Q37509169-5CDBB9DA-3E61-4C51-A727-A806006958E7Q37591164-E59ADF4B-1718-49C6-9280-9121631E159BQ37823976-5330E506-4CAD-49AC-855F-BBC8651DC842Q37893694-A9DEB385-B639-4EA0-AFFE-EE9AC8E9C0A6Q38022224-2F4B1D05-AA36-44B7-84A5-C01478EEAE79Q38040078-C63D7801-A8B5-4F6C-B193-CA42E818C3A2Q38045545-FCE648A5-A5D6-48D7-8276-F503B80C8011Q38069196-60F59F18-2114-4BEA-8173-865441AB1859
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Allan D Struthers
@nl
Allan D Struthers
@sl
Allan D. Struthers
@en
Allan D. Struthers
@es
type
label
Allan D Struthers
@nl
Allan D Struthers
@sl
Allan D. Struthers
@en
Allan D. Struthers
@es
prefLabel
Allan D Struthers
@nl
Allan D Struthers
@sl
Allan D. Struthers
@en
Allan D. Struthers
@es
P106
P1153
35427550600
P21
P31
P496
0000-0002-2926-2528